Ani Pharmaceuticals (ANIP) Retained Earnings (2010 - 2026)

Ani Pharmaceuticals has disclosed Retained Earnings across 17 years of filings, most recently posting $479000.0 for Q1 2026.

• Retained Earnings for Q1 2026 came in at $479000.0, up 100.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $479000.0 (up 100.56% YoY), and the FY2025 annual result was $1.0 million, up 101.03% from the prior year.
• Retained Earnings came in at $479000.0 for Q1 2026 at Ani Pharmaceuticals, down from $1.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $14.1 million in Q3 2023 to a low of -$100.3 million in Q4 2024.
• The 5-year median for Retained Earnings is $479000.0 (2026), against an average of -$35.8 million.
• Peak annual rise in Retained Earnings reached 498.3% in 2022, while the deepest fall reached 1439.3% in 2022.
• Ani Pharmaceuticals' Retained Earnings stood at $12.2 million in 2022, then sank by 758.55% to -$80.1 million in 2023, then slipped by 25.14% to -$100.3 million in 2024, then soared by 101.03% to $1.0 million in 2025, then plunged by 53.63% to $479000.0 in 2026.
• The last three Retained Earnings figures came in at $479000.0 (Q1 2026), $1.0 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.